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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 



















• The term ‘lockdown’ is 
not well-defined. Here the 
authors propose a two-




measures based on 
where they are 
compulsory or voluntary 
and whether they are 
targeted at identifiable 
individuals and facilities, 
or applied 
indiscriminately to a 
general population 
• The design, timing and 
implementation of 
lockdown in 9 SSA 
countries is described 
• The paper highlights the 
need for intersectoral and 
transdisciplinary research 
capable of providing a 
rigorous and holistic 
assessment of the harms 

















• Knowing environmental 
stability of SARS-CoV-2 
is required to determine 
the risks of fomite 
transmission from 
contaminated surfaces 
• This study measured the 
survival rate of infectious 
SARS-CoV-2 on several 
common surface types at 
different temperatures.  
• Note all done in the dark 
to negate any effects of 
UV light and this study 
did not use fresh human 
mucus as a vehicle to 
spread the virus – a 
hostile environment for 
viruses 
• Viable virus was isolated 
for up to 28 days at 20oC 
from common surface 
such as glass, stainless 
teel and both paper and 
plastic banknotes. Viable 
virus survived less that 
24h at 40oC on some 
surfaces. 
• Findings demonstrate 
SARS-CoV-2 can remain 
infectious for significantly 
longer time periods than 
generally considered 
possible with 
consequences for risk 
mitigating procedures to 





















• Rapid, accurate tests are 
urgently needed to improve 
patient flow and reduce 
nosocomial transmission 
• A prospective, interventional, 
non-randomised, controlled 
study of molecular point-of-
care (POC) testing in patients 












with suspected C19 to a 
hospital in the UK 
• POC testing is associated 
with large reductions in time 
to test results and could lead 
to improvements in infection 
controls measures and 
patient flow compared with 

























effective and safe in 
treatment of people 
with COVID-19 as 
more evidence 
becomes available  
• This is the second 
living update of the 
review 
• 19 studies with 
36,081 who received 
convalescent plasma 
were included 





• Authors conclude 
that it remains 
uncertain whether 
plasma from people 
who have recovered 
from C19 is an 
effective treatment 
for people 
hospitalised with C19 
and whether 
convalescent plasma 





















• This review 
evaluates the 
effectiveness and 
harms of remdesivir 
for C19 
• Four randomised 
trials were included 
• Low certainty 
evidence with few 
published trials. 
Trials excluded 
pregnant women and 
adults with severe 
kidney or liver 
disease 
• In hospitalised adults 




adverse events and 
may reduce mortality 
and time to clinical 
improvement 





oxygenation, a 5-day 
course of remdesivir 
may provide similar 
benefits to and fewer 














The Lancet | 
Article 
• Results of a 




in patients admitted 
to hospital with 
COVID-19 
• In patients admitted 
to hospital with C19, 
lopinavir-ritonavir 
was not associated 
with reductions in 28-
day mortality, 
duration of hospital 
stay, or risk of 
progressing to 
invasive mechanical 
ventilation or death 
Lopinavir-
ritonavir 
• These findings do not 
support the use of 
lopinavir-ritonavir for 
treatment of patients 
admitted to hospital 
with C19 
• Guidelines where 
lopinavir-ritonavir is 
recommended for 
treatment of patients 
admitted to hospital 
with C19 should be 
updated 













• Despite progress being made 
since 2000, stillbirths have 
not declined as rapidly as 
maternal and new born 
mortality 
• If the current trends continue, 
an additional 19 million 
stillbirths will take place 
before 2030 
• More than 200,000 additional 
stillbirths could also occur 
over the next 12 months in 
117 LMICs due to severe 
C19-related disruptions in 




















• A gender-inclusive action plan 
to enable states, the private 
sector and civil society to 
implement a faster, fairer and 
more sustainable economic 
recovery from the COVID-19 
pandemic 
• Developed from a series of 5 
virtual roundtables and a three-





























• This paper makes the 
case for a rational 
approach to public 
sector health spending 
and decision making 
during and in the early 
recovery phase of the 
COVID-19 pandemic 
• Based on ethics and 
equity principles, it is 
crucial to ensure that 
patients not infected by 
COVID-19 continue to 
get access to 
healthcare and that the 
services they need 
continue to be 
resourced 
• A list of 120 essential 
non-COVID-19 health 
interventions is 
provided, based on the 
Disease Control 
Priorities-3 highest 
priority package (HPP) 
• Adjustments of HPP 
was made based on 













ODI | Briefing 
paper 
• Highlights key 
recommendations from 
a roundtable to discuss 
how Somalia can 
strengthen its health 
system sustainably in 
the long-term 







Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
12.10.2020 ‘Drastic rise’ in Malawi’s suicide rate linked to 
Covid economic downturn 
The Guardian Global 
Development | News 
05.10.2020 What are monoclonal antibodies – and can 
they treat Covid-19? 
Wellcome | Explainer 
09.10.2020 When numbers don’t speak for themselves: 
COVID-19 and thoughts on how to measure 
a country’s performance 
CGD | Blog 
08.10.2020 Near-patient SARS-CoV-2 molecular 
platforms: new-old tools for new-old 
problems 
The Lancet Respiratory 
Medicine | Comment 
10.10.2020 Mental health: time to invest in quality The Lancet | Editorial 
08.10.2020 The intersection of COVID-19 and mental 
health 
The Lancet Infectious Diseases 
| Editorial 
07.10.2020 Scientists keep an open line of 
communication with the public 
Nature Medicine | Editorial 
06.10.2020 Mortality data I COVID-19 and beyond: the 
bedrock of Global Health Security 
CGD | Blog 
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  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  



















Nigeria CDC  Norwegian Institute 
of Public Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 




US NIH   Our World in 
Data: C19 
Testing 






Our World in 
Data  
  Singapore   Our World in Data: 
C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 Primer Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 




African Union BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria CDC Bulletin of 
the WHO 
















g in low 
resource 
settings 
























  Social 
Development 
Direct C19 blog 
series 















Institute of Public 
Health 
    




Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Online event 1h30 CGD, GF, AU 
Impact of COVID-19 
across Africa 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 















Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 




WHO Academy and 
WHO Info mobile 
applications 





















5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 









online brief with Dr 
David Nabarro 






























the Novel Coronavirus 
Online 
learning 




































of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
 
